Share on StockTwits

Veracyte (NASDAQ:VCYT) Director Evan/ Fa Jones sold 16,650 shares of the company’s stock on the open market in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $15.07, for a total value of $250,915.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Veracyte (NASDAQ:VCYT) traded down 0.48% during mid-day trading on Thursday, hitting $14.63. The stock had a trading volume of 23,567 shares. Veracyte has a 52-week low of $10.88 and a 52-week high of $19.00. The stock has a 50-day moving average of $13.80 and a 200-day moving average of $14.78. The company’s market cap is $309.7 million.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter in the prior year, the company posted ($9.04) earnings per share. The company’s quarterly revenue was up 70.5% on a year-over-year basis. On average, analysts predict that Veracyte will post $-1.32 earnings per share for the current fiscal year.

VCYT has been the subject of a number of recent research reports. Analysts at Cowen and Company raised their price target on shares of Veracyte from $17.00 to $22.00 in a research note on Wednesday, March 19th. They now have an “outperform” rating on the stock. Analysts at Leerink Swann raised their price target on shares of Veracyte from $21.00 to $23.00 in a research note on Wednesday, March 19th.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.